

A Novel Class of Drug Modalities: Generation of Molecular-targeting Helix-loop-helix Peptides via Directed Evolution in Phage-displayed Libraries

Ikuo Fujii*

Department of Biological Science, Osaka Metropolitan University, Sakai 599-8531, Japan
E-mail: fujii@omu.ac.jp

Antibodies are indisputably the most successful reagents in molecular-targeting therapy. However, the use of antibodies has been limited due to the biophysical properties and the cost to manufacture. To enable new applications where antibodies show some limitations, we have developed an alternative-binding molecule with non-immunoglobulin domain. The molecule is a helix-loop-helix (HLH) peptide, which is stable against enzyme degradations *in vivo* and is too small to show immunogenicity. Here, we introduce our HLH molecular-targeting peptides that show antibody-like functions, high affinity and high specificity for the targeted proteins.

Since the HLH peptide folds by virtue of hydrophobic and electrostatic interactions between the amino acid residues positioned inside the molecule, the outside solvent-exposed residues are possible to be mutated with a variety of amino acids to give a combinatorial library of the HLH peptides. Based on our technology of phage-displayed libraries for antibodies, we constructed a

phage-displayed library of the HLH peptides. The library was screened against G-CSF receptor to give a binding peptide, which was cyclized by a thioether linkage between the N- and C-termini. The cyclic peptide showed a strong binding affinity (K_d of 4 nM) to the receptor and a long half-life (>2 weeks) in mouse sera, proving an enzyme-resistant property¹. Immunization of the HLH peptide to mice showed no induction of the antibody production (non-immunogenic). We have applied our HLH peptide libraries for CTLA4², VEGF^{3,4}, kinases⁵, HSA⁶ to obtain their molecular-targeting HLH peptides. In addition, we used the HLH peptide as a scaffold for generating cell permeable targeting peptides through bi-functional grafting: epitope grafting to provide binding activity and arginine grafting to endow cell-permeability⁷. The HLH peptides provide insights into *de novo* peptide-based drug discovery and then would be a new therapeutic modality.

References

- ¹ Fujiwara, D., Fujii, I., *Current Protocols in Chemical Biology* **2013**, 5, 171-194.
- ² Tharanga M.R. Ramanayake Mudiyansele, *et al.*, *ACS Chem. Biol.* **2020**, 15, 360–368.
- ³ Michigami, M., *et al.*, *PLoS ONE*, **2021**, 16(2): e0247045.
- ⁴ Michigami, M., *et al.*, *ACS Chemical Biology*, **2022**, 17, 3, 647–653.
- ⁵ Fujiwara, D., *et al.*, *ChemBioChem*, **2021**, 22, 3406-3409.
- ⁶ Nakatani, Y. *et al.*, *ACS Mol. Pharmaceutics*, **2022**, 19, 2279–2286.
- ⁷ Fujiwara, D, *et al.*, *Angew. Chem. Int. Ed.* **2016**, 55, 10612-10615.



Ikuo FUJII. Kyushu University (Ph.D., 1986, Advisor Ken Kanematsu), The Rockefeller University (Postdoc, 1988, Advisor Emil T. Kaiser), The Scripps Research Institute (Senior Research Scientist, 1989, Advisor Richard A. Lerner), Protein Engineering Research Institute (PERI) (Research Director, 1991), Osaka Prefecture University (Professor, 2003), Osaka Metropolitan University (Specially Appointed Professor, 2022-present). [Field of research] Directed evolution of artificial enzymes, proteins and peptides in phage-displayed combinatorial libraries “Abzymes & Molecular-targeting peptides”